Objective To investigate the expressions of immune inflammation indicators, such as the neutrophil-to-lymphocyte ratio (NLR), high sensitivity C-reactive protein (hs-CRP), homocysteine (Hcy), red blood cell distribution width (RDW) and antinuclear antibody (ANA) in patients with recurrent schizophrenia, and their relationships with abnormal glucose and lipid metabolism.
Methods A total of 70 patients with recurrent schizophrenia were selected as case group, and 48 healthy subjects were selected as control group. The expressions of NLR, RDW, hs-CRP, Hcy and ANA were compared in two groups. A total of 33 patients who were treated with first-line second generation antipsychotics for 1 month were selected from the case group, and the expressions of NLR, RDW, hs-CRP and Hcy before and after treatment were compared. The univariate and multivariate binary Logistic regression analysis were used to analyze the relationships between the immune inflammatory indicators such as NLR, RDW, hs-CRP, Hcy and the abnormal glucose as well as lipid metabolism in patients in the case group.
Results The NLR, RDW, hs-CRP and Hcy in the case group were significantly higher than those in the control group at admission(P < 0.05). There was no difference in ANA between two groups (P>0.05).The NLR levels of 33 patients who received first-line second-generation antipsychotic treatment for 1 month were lower than those at admission (P < 0.05). There were no differences in RDW, hs-CRP and Hcy levels before and after treatment (P>0.05). Logistic regression analysis showed that NLR and age were significantly correlated with abnormal fasting glucose metabolism in patients with recurrence of schizophrenia (OR=1.799, 1.063, respectively, P < 0.05), hs-CRP and age were correlated with abnormal lipid metabolism in patients with recurrent schizophrenia (OR=1.273, 1.031, respectively, P < 0.05).
Conclusion Hcy, hs-CRP, NLR and RDW may play important roles in the pathogenesis of recurrent schizophrenia. The NLR and hs-CRP levels may be related to abnormal glucose and lipid metabolism in patients with recurrent schizophrenia.